Summary & Overview
Other Antepartum Diagnoses without O.R. Procedures with CC: Inpatient Reimbursement Overview
DRG 832 encompasses nonoperative antepartum admissions where a Complication or Comorbidity is documented, such as medical management of pregnancy complications requiring inpatient care. It matters for inpatient reimbursement because the Complication or Comorbidity designation increases the case weight and influences Medicare payment under Diagnosis-Related Group classification.
DRG 832 Overview
DRG 832 covers inpatient admissions for other antepartum diagnoses without operating room procedures when a Complication or Comorbidity is present. Typical cases include management of symptomatic pregnancy-related conditions that require observation, monitoring, or medical treatment but not surgery. This Diagnosis-Related Group matters for Medicare inpatient payment because the presence of a Complication or Comorbidity elevates relative weight and reimbursement compared with cases without such comorbid conditions. Payers and hospitals use this grouping to align clinical resource use with Medicare Severity Diagnosis-Related Group payment methodologies.
Clinical Trials
- Trials evaluating optimized inpatient management protocols for acute antepartum complications without operative intervention: these studies compare different monitoring strategies, medication regimens (e.g., antihypertensive titration algorithms, tocolytic use when appropriate, or corticosteroid timing), and escalation criteria for patients admitted with non-surgical antepartum diagnoses and coexisting complications. The patient population includes pregnant individuals hospitalized for conditions such as preeclampsia with mild-to-moderate features, threatened preterm labor managed without immediate surgery, or significant antepartum bleeding not requiring operative control. Evidence from these trials informs clinical pathways that can reduce length of stay, decrease maternal-fetal adverse events, and help payers and hospitals standardize resource utilization for this DRG.
- Comparative effectiveness studies of adjunctive maternal-fetal diagnostic and surveillance technologies in complicated antepartum admissions: research compares outcomes and cost-effectiveness of intensified fetal surveillance (e.g., biophysical profile frequency, continuous versus intermittent fetal monitoring), urinary or serum biomarker panels for worsening disease, and remote monitoring integration during hospitalization. These studies enroll hospitalized pregnant patients with antepartum conditions that carry increased risk (for example, growth restriction, hypertensive disorders with CCs, or abnormal antenatal testing) to determine which surveillance approaches best predict deterioration and guide timely interventions. Results are relevant to clinicians and payers because they can identify surveillance strategies that improve maternal and neonatal outcomes while avoiding unnecessary ICU transfers or prolonged admissions billed under this DRG.
- Longitudinal outcomes and health services research on postpartum and neonatal resource use after complicated antepartum admissions: these observational cohort studies follow patients admitted for non-operative antepartum diagnoses with complications to assess postpartum readmission rates, mental health outcomes, lactation success, and neonatal intensive care utilization up to 6–12 months postpartum. The populations studied include those with antepartum complications such as severe hypertension, medically managed abruption concerns, or significant antepartum hemorrhage that did not require surgery, aiming to quantify downstream healthcare utilization and morbidity. Findings help providers and payers understand downstream costs and identify opportunities for targeted discharge planning, transitional care interventions, and reimbursement models that address longer-term needs stemming from admissions in this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.